IBPI completes Protegrin Phase III enrollment

IntraBiotics (IBPI) completed enrollment in a Phase III study of its Protegrin IB-367 synthetic antimicrobial peptide analog rinse to treat ulcerative oral mucositis in chemotherapy patients. The comp...